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We describe the eﬀect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura
(ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy.
One month after the last rituximab administration a healthy girl was born. She had normal growth and development during the
ﬁrstsixmonths.Atbirth,B-lymphocyteswerenotdetectable.Rituximablevelsinmotherandneonatewere24000and6700ng/mL,
respectively. Only 7 cases of rituximab administration during pregnancy were described. No adverse events are described for fetus
and neonate. We demonstrate that rituximab passes the placenta and inhibits neonatal B-lymphocyte development. However,
after 6 months B-lymphocyte levels normalized and vaccination titres after 10 months were adequate. No infection-related
complications occurred. Rituximab administration during pregnancy appears to be safe for the child but further studies are
warranted.
Copyright © 2008 D. T. Klink et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Management of a pregnant patient with immune-mediated
thrombocytopenia (ITP) is similar to that of nonpregnant
patients [1]. Corticosteroids are very eﬃcient and inexpen-
sive and commonly used for this indication [2]. Although
consideredgenerallysafe,steroidshavebeenreportedtohave
adverse eﬀects, including oral clefts and osteoporosis [3].
Intravenous immunoglobulins (IVIGs) are a good alterna-
tive. In case of refractory ITP in pregnant patients, a com-
bination of corticosteroids and IVIG can be given. Similar
to nonpregnant patients, a splenectomy can be considered.
Remission of ITP is achieved in 70% of pregnant women
after splenectomy [4]. When splenectomy is considered it
should be performed in the second trimester of pregnancy.
TheaimoftreatmentofITPinpregnancyisadequateplatelet
count to reduce the risk of hemorrhage during labour. Both
mother and neonate are at risk for severe bleeding as low-
neonatal platelet count occurs in 20–25% of the oﬀspring of
ITP patients [5]. When conventional therapy fails, treatment
with third- and fourth-line medications for refractory ITP is
indicated. Unfortunately, their safety during pregnancy has
not been established. For example, azathioprine is associated
withintrauterinegrowthretardationandimmunosupression
[6,7],andmedicationssuchasdanazolandvincristinshould
beavoidedduetotheirteratogenicity[8].I no r d e rt op r o vid e
safealternativesduringpregnancy,noveltreatmentstrategies
are under investigation for the management of ITP. These
innovative approaches include thrombopoietin, anti-CD40
ligand, and rituximab, a monoclonal anti-CD20 antibody
[1].
Rituximab is a chimeric human and murine mono-
clonal antibody and targets the CD20 antigen expressed
on pre-B cells and mature B-lymphocytes [9]. Rituximab-
opsonized B-cells are destroyed by at least three pathways:
lysis through complement-mediated cytotoxicity, opsonic
phagocytosis, and natural killer cell-mediated cytotoxic-
ity [10]. The antibody was originally developed for the
treatment of B-cell lymphoma [11]. Recently, however,
the use of rituximab is expanded to the treatment of2 Clinical and Developmental Immunology
diﬀerent autoimmune diseases including ITP [12]. The
number of (autoreactive) B-cells is diminished in patients
treated with rituximab. Since rituximab is an IgG-based
antibody, it may cross the placenta and then inter-
fere with fetal and neonatal B-cell development, poten-
tially leading to immune deﬁciency and increased sus-
ceptibility to infections in the neonate. However, few
data are available on the use of rituximab during preg-
nancy.
We present a case report on the eﬀects of rituximab
on a child after exposure during third trimester preg-
nancy. In addition, we performed a literature search for
additional data in order to gain more insight on the
safety aspects of rituximab administration during preg-
nancy.
Case
A 36-year-old woman was diagnosed with ITP since 1994.
At that time during pregnancy, ITP was successfully treated
with corticosteroids. In 1997, a splenectomy was performed.
During present pregnancy, she was initially treated with
corticosteroids and IVIG, but the platelet count only rose
from 16 × 109/L to 27 × 109/L with persisting hemorrhagic
diathesis.Subsequently, she was referred to our hospital and
treated for refractory ITP with 60mg prednisone daily.
This treatment was continued during pregnancy until two
weeks prior to delivery. In addition, from week 30 to week
34, she also received rituximab 375mg/m2 intravenously
weekly for 4 consecutive weeks. Due to persisting low-
platelet count, rituximab administration was ceased and
IVIG administration was started for two consecutive days
a t3 7w e e k sa n d6d a y so fg e s t a t i o n .A t3 8w e e k sa n d2
days of gestation and one month after the last rituximab
administration, labour was induced with prostaglandins.
For comfort, the mother received promethazine orally and
pethidine intravenously until one hour before birth. A
slightly depressed girl was born with apgar scores of 7, 8,
and 8 at 1, 5, and 10 minutes, respectively. Birth weight was
3780 grams (90th–95th percentile weight for gestational age
according to Kloosterman [13]), length was 46 centimetre
(cm) (third percentile length for gestational age [14]),
and head circumference was 36cm (98th percentile head
circumferenceforgestationalage[14]).Physicalexamination
revealed no abnormalities. Cord blood samples were taken
for blood gas analyses and measurement of thrombocytes,
lymphocyte characterization, and rituximab levels. Because
of the administration of opiates intravenously prior to birth,
the slightly depressed neonate was subsequently admitted
to the high-care facility of our neonatology department for
observation. In the next 24 hours, she quickly recovered
spontaneously and no adverse events occurred. The patient
was transferred to the maternity ward and discharged on the
fourth day after birth. She was followed up in the outpatient
clinic for pediatric infectious diseases and immunology of
our hospital. Up to the age of 10 months, she developed
normally, and growth was not impaired. She did not
have any infectious complications. Vaccination titres were
normal.
2. METHODS
2.1. Rituximabserumlevelmeasurement
The rituximab serum levels in cord blood were measured
using enzyme-linked immunosorbent assay (ELISA) at
Xendo Drug Development, Groningen, The Netherlands.
Coeﬃcient of variation was between 4.7% and 8.2%.
2.2. Flowcytometry
Lymphocyte characterization was performed at the Depart-
ment of Pathology. For this purpose, whole blood was
incubated in Trucount tubes with ﬂuorochrome-conjugated
monoclonal antibodies directed against lymphocyte asso-
ciated markers CD3, CD4, CD8, CD16/56, CD19, CD20,
CD27, and CD45 (BD Biosciences, San Jose CA). After
red cell lysis, lymphocyte subsets were analyzed by multi-
parameter ﬂow cytometry (FACSCalibur, BD Biosciences).
B-lymphocytes were quantiﬁed as the fraction of CD19
positive cells within the CD45 positive total lymphocyte
gate.B-lymphocytematurationandmemoryformationwere
analyzed as the percentage of CD19 and CD20 positive, and
CD19 and CD27 positive cells within the total lymphocyte
gate, respectively.
2.3. Reviewoftheliterature
Two Embase.com searches were performed on May 1,
2007, with EMTree-terms: (1) (“rituximab”/exp/dd ae
(adverse drug reaction), dd it (drug interaction), dd to
(drug toxicity) AND (“newborn”/exp OR “infant”/exp
OR “fetus”/exp OR “embryo”/exp OR “pregnancy”/exp))
which resulted in 19 references; (2) (“rituximab”/exp AND
“pregnancy”/exp)—54 references. Duplicate references from
both searches were removed, resulting in 42 references. Titles
and abstracts identiﬁed were examined to select potentially
relevant studies. In addition, reference lists of identiﬁed
studies and review articles were examined.
3. RESULTS OF REPORTED CASE AND
LITERATURE SEARCH
Our literature search resulted in 7 additional case reports on
rituximabuseduringpregnancy.Therelevantdataof8cases,
including our case, are summarized in Table 1.
3.1. RituximablevelsandB-lymphocytesinthemother
In the majority of the cases, the indication for rituximab was
the presence of a B-cell malignancy. In 3 cases, including
our case, the indication was a haematological disorder which
involved the immune system. Regardless of the indication,
the dosage was the same in all cases with a frequency of
either once a week or every 14 days. Repetition of dosage
was either 4 or 6 times. In combination with nonalkylating
chemotherapy (CHOP), rituximab was eﬀective in reducing
t u m o r l o a di n5c a s e s( Table 1) .I n2c a s e s[ 15, 16]a n do u r
case, maternal B-cell numbers were determined at the day
of birth and were not detectable. Decker et al. [15]r e p o r t e dD. T. Klink et al. 3
Table 1: Summary literature search.
Mother Herold
2001
Kimby
2004
Friedrichs
2006
Scully M
2006
Ojeda-Uribe
2006
Magloire
2006
Decker
2006
Current
study
Condition B-cell
lymphoma
NH-
lymphoma
Burkitt
lymphoma
Thrombotic
Thrombocy-
topenic
Purpura
Autoimmune
Haemolytic
anaemia
Burkitt
lymphoma
B-cell-NH
lymphoma ITP
Rituximab
375mg/m2 Weekly 4x Weekly 4x Weekly 4x Weekly 4x — — Biweekly
6x Weekly 4X
Co medication CHOP(1) —C H O P Plasma
exchange Corticosteroids CHOP CHOP Prednisone,
IgG
Administration
time GA Week 21 Week -1 to
3
Weeks
16–30 Week 27 Week 10 Week 13 to
?
Weeks
16-28
Week 30 to
34
Rituximab level
D0(2)(ng/mL) — — 9750 — — — 25000 24000
CD19+ B-cells
D0 (1 × 109/L) ——0 — — —0 0
Child ———— — ———
G A ( w e e k s ) 3 54 04 13 0 3 8 3 93 33 8
Rituximab level
D0 (ng/mL) — — 32095 — — — 30000 6700
CD19+ B-cells
(1 × 109/L) <
week 1 post
partum
— 0,1 0 — 0,66 — approx
0,05 0,08
CD19+ B-cells
(1 × 109/L) 1
month
normal — — — 1,98 — — 0,00
CD19+ B-cells
(1 × 109/L) 3
months
———— — ——0 , 2 1
CD19+ B-cells
(1 × 109/L) 6
months
———— — ——2
Vaccination
titres — Normal Normal — — — Normal normal
IgA; IgM; IgG
(g/L) 1-2
months
— — — — 0,07; 0,3; 4,5- — — <0,07; 0,05;
6,1
IgA; IgM; IgG
(g/L) 3 months ———— — ——<0,07;
<0,04; 2,8
IgA; IgM; IgG
(g/L) ≥6
months
— IgG
normal Normal — — — Normal 0,16; 0,53;
2,2
(1) Cyclophosphamid, doxorubicin, vincristin, prednisolon.
(2) Day of birth.
a reconstitution of maternal B-cells 12 weeks after delivery
coinciding with a large decrease in serum concentration
of rituximab. At birth, the maternal rituximab levels were
reported to be approximately 25mg/L when administrated
a month prior to delivery. We have found equal rituximab
levels in our case. Friedrichs et al. [16] reported a lower
level of 9.7mg/L, but in this case, report rituximab was
administrated around 12 weeks prior to delivery. When
followed up, the rituximab levels decreased corresponding
with its known half-life time [15, 16].4 Clinical and Developmental Immunology
100
101
102
103
104
C
D
1
9
P
E
100 101 102 103 104
CD20 FITC
(a)
100
101
102
103
104
C
D
1
9
P
E
100 101 102 103 104
CD27 FITC
(b)
Figure 1:Flowcytometricanalysisofperipheralbloodlymphocytes,takenfromtheneonateattheageofsixmonths,indicatingthepresence
of CD19 positive B-lymphocytes (20% on average; (a) and (b)), expressing the maturation marker CD20 (99%; (a), and partly expressing
the memory marker CD27 (7%; (b). Analysis was done within the CD45 positive total lymphocyte gate.
3.2. RituximablevelsandB-lymphocytes
intheneonate
At birth, the neonatal rituximab level in our case was
6.7mg/L. Two other authors reported neonatal rituximab
levels at birth: Friedrichs et al., and Decker et al. reported
a level of 32mg/L and 30mg/L, respectively. Both authors
reported a decline in rituximab levels consistent with the
known half-life time of rituximab.
In 2 cases [15, 16] and our case, the number of neonatal
B-cells at time of delivery was determined and was unde-
tectable by ﬂow cytometry. Time of rituximab adminis-
tration during gestation did not appear to inﬂuence this
outcome. In our case, the number of B-lymphocytes demon-
strated a steady increase over time. Although the number of
B-cells was still zero 3 weeks after birth, a rise was detected
after 3 months. At the age of 6 months, the number of
B-cells was in the normal range both in absolute and in
relative numbers. Moreover, at this time, all peripheral B-
cells were mature as indicated by CD20 positivity, and B-
cell memory formation could be demonstrated by CD27
positivity (Figure 1). In addition, normal immunoglobulin
(IgG) levels could be demonstrated which is consistent with
ﬁndings in other case reports. In our case and in 3 other
cases, [15–17] normal vaccination responses were found.
3.3. Clinicaloutcomeoftheneonate
During pregnancy, fetal growth and development were
monitored and turned out to be normal. Indeed, in our case,
the patient’s birth weight was between the 90th and 95th
percentile [13], within the normal range of birth weight in
the Dutch population (outer limit is 97th percentile).
Five out of eight neonates were born at term age
(Table 1). Of the three preterm neonates, one was delivered
by caesarean section due to deterioration of the maternal
condition [18]. No apparent cause for the preterm birth
was reported in the other two neonates. Only one neonate
[19] was described to have been treated with antibiotics
for suspicion of perinatal infection. All other children did
not have any complications in the neonatal period. More
importantly, no single adverse event occurred.
In our case, the neonate was admitted to the high-care
facilityforobservationduetomaternalintravenouslyopiates
administration. The arterial umbilical cord blood gas anal-
ysis was pH 7.26, CO2 57.0mmHg, 25.0 HCO3
− mmol/L,
and base excess −3.1mmol/L, indicating little intrauterine
hypoxicstress.Althoughourpatientwasslightlydepressedat
birth,shequicklyrecovered.Thus,theneedforfurtherblood
gas analysis was eliminated.
All the children had normal growth and development.
No clinical signs of impaired immunity were observed.
4. DISCUSSION
Rituximab is generally considered safe for the treatment
of both malignant and nonmalignant diseases. Although
frequently used in women who are fertile, little is known
about the safety aspects during pregnancy. Since rituximab
is a chimeric antibody of the IgG isotype, it is likely to
cross the placental barrier, and one should consider the
risk of B-cell depletion in the child. To our knowledge, inD. T. Klink et al. 5
vitro studies on placental transfer of rituximab have not
been reported, but rituximab levels could be demonstrated
in the exposed neonate. In our case, rituximab levels were
3.5 times lower in the neonate at birth when compared
to the serum concentrations of the mother. This is in
contrast with previously reported cases [15, 16] in which the
rituximab levels in the cord blood were higher compared
to maternal levels. As rituximab was administrated in the
second trimester in these cases, time of administration
during the pregnancy may contribute to this diﬀerence.
Maternal IgG is transferred across the placenta by means
of a speciﬁc receptor-mediated mechanism. Mother-to-fetus
IgG transfer starts at week 16 of gestation. After 22 weeks
of gestation, the fetal IgG levels increase rapidly [20]. Thus,
when rituximab exposure starts at gestational age 16 weeks,
as occurred in the two cases reported [15, 16], there has
been a maximum period of opportunity for transfer. In our
case, exposure was relatively short prior to birth. Although
most of IgG is acquired in the last 4 weeks of pregnancy,
the exposure may not have been long enough to reach
the levels previously reported. Despite the lower level of
rituximab in the cord blood, the number of neonatal B-
lymphocytes at birth was zero. This is similar to previous
reports [15, 16, 18, 19]. During follow-up, all children
showed an increase of B-lymphocytes to the age-speciﬁc
normal reference levels demonstrating the transient eﬀect of
rituximab (Table 1). Reconstitution of B-cells coincided with
the known half-life of rituximab. Although B-cell function
was initially impaired, the clinical outcome of all patients
was good. None of the patients had serious infection-related
complications. The explanation for this ﬁnding may be the
fact that in the ﬁrst few months of life, the neonate largely
depends on maternal IgG for immunity, and B-cell function
still has to develop. The rituximab eﬀect may already be
diminished properly before the infant depends on its own B-
cellfunction. ThedataofadequateIgGandvaccinationtitres
are supportive of this.
Although the therapeutic beneﬁt of rituximab in malig-
nancies is well established, its eﬃcacy in the treatment of
autoimmune diseases is still under investigation. Likewise,
the exact mechanism(s) by which the B-cell depletion pro-
moted by rituximab ameliorates autoimmune disease activ-
ity remains unclear. Despite lack of complete understanding
of how rituximab targets autoimmune diseases, the antibody
has been applied in the treatment of various ailments such
asrheumatoidarthritis(RA),SystemicLupusErythematosus
[21, 22], and ITP [12]. Early success with rituximab in ITP
has led to its widespread use and incorporation into recent
treatment schemes. A meta-analysis by Arnold et al. demon-
strated [23] that rituximab was associated with a platelet
count response deﬁned as > 50 × 109 cells/L. However, none
of the identiﬁed studies included a control group and none
met all predetermined methodological quality criteria for
observational studies. The eﬃcacy of rituximab compared
with standard treatments for ITP could not be determined,
and the authors strongly urge for randomized controlled
trials.
In our case, rituximab administration did not result in
increasedplateletcountandrituximabwasstoppedandIVIG
treatment was started. This ﬁnding underlines the need for
additional data to determine the eﬀectiveness of rituximab
for ITP in pregnant women.
5. CONCLUSION
Intrauterine exposure to rituximab appears not to be harm-
ful to the neonate as neither in the literature nor in our
case any complications related to rituximab are reported.
However, data are limited to a handful of case reports,
and caution should be taken when considering rituximab
administration during pregnancy. In addition, rituximab
should not be used indiscriminately, but should be reserved
for carefully selected cases when ﬁrst and second line therapy
fails.Furtherstudiesarewarrantedtofullyevaluatethesafety
of rituximab during pregnancy.
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